title: Lessons learned and future hopes: three thousand renal transplants at the University of Minnesota.
abstract: 1. The experience of 3,183 transplants between June 7, 1963 and September 30, 1990 at the University of Minnesota was reviewed. 2. Patients were divided into 4 historical periods-each era was associated with improved outcome. 3. As results have improved, the proportion of patients less than 5 years old and the proportion greater than 50 years old have increased. Type I diabetes has become the most common cause of renal failure in patients transplanted here. 4. The most important variable leading to improved outcome was donor source. Both HLA-identical and HLA-nonidentical LRD transplants have better outcome than CAD transplants (p less than 0.0001). 5. Multivariate analyses were done to determine risk factors for survival: a) in the first year, and b) in subsequent years. In the first year, age greater than 50, diabetes, and retransplantation had an adverse affect whereas LRDs and CsA immunosuppression were beneficial. Similar factors affected survival after the first year. HLA mismatch had no impact. 6. When death with graft function was excluded, diabetes and age greater than 50 were no longer risk factors, suggesting that the excess graft loss in these groups was due to patient death. 7. Chronic rejection and death with function remain the predominant causes of graft loss. 8. As protocols have evolved, results have improved, and previously "high-risk" patients are being successfully transplanted. Future efforts should be directed at decreasing graft loss from rejection and death with function.
authors.affiliation: Department of Surgery, University of Minnesota, Minneapolis.
authors.forename: R V
authors.initials: RV
authors.lastname: Perez
authors.forename: A J
authors.initials: AJ
authors.lastname: Matas
authors.forename: K J
authors.initials: KJ
authors.lastname: Gillingham
authors.forename: W D
authors.initials: WD
authors.lastname: Payne
authors.forename: D M
authors.initials: DM
authors.lastname: Canafax
authors.forename: D L
authors.initials: DL
authors.lastname: Dunn
authors.forename: P F
authors.initials: PF
authors.lastname: Gores
authors.forename: D E
authors.initials: DE
authors.lastname: Sutherland
authors.forename: J S
authors.initials: JS
authors.lastname: Najarian
mesh_terms: D000328:Adult; D000367:Age Factors; D002648:Child; D003524:Cyclosporins / Q000627:therapeutic use; D005500:Follow-Up Studies; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000276:immunology; D008910:Minnesota; D012189:Retrospective Studies; D014019:Tissue Donors
chemical_list: D003524:Cyclosporins